<DOC>
	<DOCNO>NCT01111123</DOCNO>
	<brief_summary>The purpose study determine whether combinational use ammonium lactate lotion 12 % ( Lac-Hydrin ) halobetasol propionate ointment 0.05 % ( Ultravate ) safe effective initial treatment long-term maintenance psoriasis . Patients use medication continuously two week obtain good improvement base investigator clinical assessment randomize Lac-Hydrin lotion twice daily every day placebo ointment Ultravate ointment twice daily weekend 24 week .</brief_summary>
	<brief_title>Ammonium Lactate Lotion 12 % ( Lac-hydrin® ) Halobetasol Propionate Ointment 0.05 % ( Ultravate® ) Treatment Maintenance Psoriasis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , clinical trial assess efficacy Ultravate ointment combination Lac-Hydrin lotion treatment plaque psoriasis . In first phase , patient treat two week combination therapy use Ultravate ointment twice daily along Lac-Hydrin lotion twice daily . After two week , psoriasis plaque evaluate test treatment efficacy . Those patient significant clinical improvement per investigator clinical assessment , randomize 1:1 fashion maintenance phase receive Lac-Hydrin lotion twice daily everyday placebo ointment Ultravate ointment twice daily weekend . Continuous use Ultravate ointment discontinue follow two week treatment compliance FDA indication . Patients evaluate every 4 week ( monthly ) maintenance phase . The purpose second phase study investigate whether use Ultravate weekend minimize risk plaque recurrence , maximize duration therapeutic effect , limit need use long-term continuous topical corticosteroid treatment . As well , second phase study investigate whether twice daily Lac-Hydrin lotion impact maximize duration therapeutic effect well minimize local cutaneous side effect skin atrophy telangiectasia . Part clinical study consist use patient self-assessment questionnaire use non-identifying digital photography target lesion . The hypothesis Ultravate ointment weekend statistically efficacious maintain excellent initial clinical response combination Lac-Hydrin lotion help minimize local cutaneous side effect well enhance therapeutic effect .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Halobetasol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Subjects must least 18 year age good general health confirm medical history . Females childbearing potential must negative urine pregnancy test Day 1 must agree use adequate birth control method entire study . A clear diagnosis plaque psoriasis must previously establish disease must present least 6 month . Subjects must lesions suitable evaluate response test agent . The severity disease Day 1 must rat least 2 ( Mild ) key psoriasis characteristic ( scale , erythema , plaque elevation ) . Subjects must able understand requirement study , abide restriction , return require examination . All subject must sign statement informed consent approve study . Subjects pregnant ( determined urine pregnancy test Day 1 ) . Subjects nursing . Subjects know hypersensitivity component test medication . Subjects require medication ( topical systemic ) may affect course disease study period ( e.g . antibiotic , sedate antihistamine ) . Subjects use biologics systemic treatment psoriasis within 12 week enter study . Subjects use systemic corticosteroid within 28 day enter study ; subject use topical corticosteroid topical therapy ( emollient ) location body within 1 week enter study . Subjects overt preexist telangiectasia skin atrophy intend treatment site . Subjects use medication disease judgment investigator interfere conduct interpretation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>lac-hydrin</keyword>
	<keyword>ammonium lactate</keyword>
	<keyword>Ultravate</keyword>
	<keyword>halobetasol propionate</keyword>
	<keyword>weekend application</keyword>
	<keyword>topical therapy</keyword>
	<keyword>topical corticosteroid</keyword>
	<keyword>class I steroid</keyword>
</DOC>